A regimen based on Roche's CD20xCD3 bispecific antibody Columvi has been approved in the EU as a second-line therapy for ...

近日，以“AI赋能，健康生活”为主题的第七届世界大健康产业发展大会在中国光谷科技会展中心隆重召开。大会吸引了医疗健康领域的顶尖企业家、科学家、技术专家齐聚武汉，共同探讨人工智能技术驱动下的大健康产业变革与创新实践。

为解决先进疗法药物（ATMPs）上市后风险管理问题，研究人员开展 “欧盟 2009 - 2023 年授权 ATMPs 风险最小化措施” 的研究。结果显示多数 ATMPs 授权时有额外风险最小化措施（aRMMs）。该研究为 ATMPs 监管决策提供参考。

The global CAR T-cell therapy market is on track for rapid growth, with projections indicating it will exceed USD 27.5 billion by 2033, up from USD 2.7 billion in 2025. This exponential rise in market ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

Chimeric antigen receptor (CAR) T cell therapies have made remarkable strides in treating high-risk B-cell malignancies since ...

The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...

当医学突破温暖每个平凡生命时，人类才能真正赢得对抗疾病的战争！ 顶刊《新英格兰医学杂志》公开了一项医学奇迹：德国柏林8名恶性肿瘤患者，在接受新型CAR-T细胞疗法后，不仅实现了5年无癌生存，而且其中最长生存者甚至还见证了孙子的诞生。

Discover Nkarta's groundbreaking cell therapy advancements, robust financials, and investment potential. Click here to read my most recent analysis of NKTX.

且因其制造过程复杂、高度个性化且耗时，治疗费用也非常高昂，限制了药物的可及性，从而阻碍了它的商业成功。例如，Kymriah的单次输注费用为475， 000 美元，Yescarta则为373， 000 美元，且不包括住院治疗副作用的费用，对患者个人和医疗系统都是沉重的财务 ...